Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | GNG2 | P59768 | 1/20 | 0.30 |
| ▸ | GNB1 | P62873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320265 | 1.00 | GABRA1 (0.39) | GABRA1GABRB2HSD17B3ALDH1A1KDM4E | |
| SCHEMBL5442460 | 0.89 | CYP1B1 (0.34) | GABRA1GABRB2HSD17B3ALDH1A1HPGD | |
| SCHEMBL28174921 | 0.89 | MEN1 (0.35) | GABRA1GABRB2HSD17B3ALDH1A1KDM4E | |
| SCHEMBL28569644 | 0.83 | HSD17B3 (0.39) | GABRA1GABRB2HSD17B3ALDH1A1KDM4E | |
| SCHEMBL21037083 | 0.83 | HSD17B3 (0.40) | HSD17B3ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL16632779 | 0.77 | GABRA1 (0.36) | GABRA1GABRB2TBXA2R | |
| SCHEMBL2814697 | 0.77 | TYR (0.42) | ALDH1A1KDM4EMAPTESR1MEN1 | |
| SCHEMBL2815176 | 0.77 | TYR (0.42) | ALDH1A1KDM4EMAPTESR1MEN1 | |
| SCHEMBL2813389 | 0.77 | TYR (0.42) | ALDH1A1KDM4EMAPTESR1MEN1 | |
| SCHEMBL4585477 | 0.75 | TYR (0.41) | ALDH1A1KDM4EMAPTESR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110249030-B | Organic electroluminescent device | 材料科学有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20190006592-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | MATERIAL SCIENCE CO., LTD. (KR) | 2019-01-03 | — | — | US | disclosed |
| WO-2018128470-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | 머티어리얼사이언스 주식회사 | 2018-07-12 | — | — | WO | disclosed |
| WO-2017116169-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | 머티어리얼사이언스 주식회사 | 2017-07-06 | — | — | WO | disclosed |
| US-20080015399-A1 | 1,6-Substituted 3,8-Dihalogenopyrene And Process For Producing The Same | IDEMITSU KOSAN CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190006592-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | OCIAD1, OCIAD2, ORC3 | GABRA1 4582/4885GABRB2 4299/4885HSD17B3 2507/4885 |
| US-20080015399-A1 | 1,6-Substituted 3,8-Dihalogenopyrene And Process For Producing The Same | CCNL2, CYP1A1, AHR | GABRA1 4725/4885GABRB2 4772/4885HSD17B3 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.